Rosuvastatin Sun 10 mg film - coated tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

rosuvastatin sun 10 mg film - coated tablets

Унифарм - АД - 10 mg film - coated tablets

Rosuvastatin Sun 20 mg film - coated tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

rosuvastatin sun 20 mg film - coated tablets

Унифарм - АД - 20 mg film - coated tablets

Rosuvistat 40 mg film - coated tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

rosuvistat 40 mg film - coated tablets

Унифарм - АД - 40 mg film - coated tablets

Lipanthyl Supra 160 mg film - coated tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

lipanthyl supra 160 mg film - coated tablets

mylan medical sas - Фенофибрат - 160 mg film - coated tablets

Lipanthyl 200 M 200 mg capsules, hard বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

lipanthyl 200 m 200 mg capsules, hard

mylan medical sas - Фенофибрат - 200 mg capsules, hard

Waylivra ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

waylivra

akcea therapeutics ireland limited - volanesorsen натрий - Хиперипопротеинемия тип i - Други гиполипидемические модифициращи добавки - waylivra е показан като допълнение към диетата при възрастни пациенти с генетично потвърждение на семейния chylomicronemia синдром (fos) и висок риск за развитие на панкреатит, в които отговорът на диета и триглицериди антигипертензивная терапия е неадекватна.

Kynamro ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

kynamro

genzyme europe bv - мипромерен натрий - Хиперхолестеролемия - Сърдечносъдова система - лечение на холестерола и хиперхолестеролемия,.

Vazkepa ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

vazkepa

amarin pharmaceuticals ireland limited - icosapent ethyl - Дислипидемиите - Липидни модифициращи агенти - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Evkeeza ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

evkeeza

ultragenyx germany gmbh - evinacumab - Хиперхолестеролемия - Липидни модифициращи агенти - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).